Riding The Tailwind Of Healthtech Through The Pandemic And Beyond
COVID-19 Has Not Put The Brakes On Resurgence Of Health Care, Say Asia-Based VC Investors
Executive Summary
VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.
You may also be interested in...
Mining The Deep Tech Seam Of Innovation For Healthtech Gold
Singapore-based SGInnovate has a unique multi stakeholder business model focused on identifying and funding Deep Tech start-ups. CEO Jui Lim now plans to increase the group’s activity in advanced manufacturing and “wetware” ̶ drugs and diagnostics – as firms increasingly are able to revert to pre-COVID business plans.
VC View: Riding The Waves Of Asia’s Healthtech Explosion
Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.
‘A Fuse Burning At Both Ends’: German Near-Term Market Outlook For Medtech Industry
Later market launch of innovations and a hit on EBITDA are simultaneously affecting medtech companies in Germany and central Europe as they strive to keep quality uppermost while battling the most frustrating confluence of negative effects on business than most companies have ever seen.